• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

Responding to COVID-19

Accelerating research to protect the most neglected

Home > News

Responding to COVID-19

Accelerating research to protect the most neglected

23 Jul 2020
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

We cannot look back on the progress of our partnerships in 2019 without acknowledging the unprecedented challenges we are facing as this report goes to print.

Over the first months of 2020, COVID-19 has overwhelmed some of the world’s most advanced health systems. As we write, the capacity of weaker health systems to manage a surge of severe cases is extremely limited, and the low availability of PPE for front-line healthcare workers in some areas means that these key staff are likely to be disproportionately affected by COVID-19.

The overwhelming majority of COVID-19 research studies are taking place in high-income countries. To help protect vulnerable communities in resource-limited settings, DNDi is mobilizing its networks to make sure their specific needs are prioritized in medical R&D for COVID-19 vaccines, diagnostics, and treatments.

“On behalf of the German Government I wish to express my gratitude that we could intensify our long-lasting collaboration with DNDi in the fight against the COVID-19 pandemic. This pandemic underlines the necessity of a global approach and shows the advantages of instruments such as product development partnerships. I am confident that DNDi’s work will speed delivery of reliable and accessible drugs and tools to all people, including the most vulnerable.”

Anja Karliczek, Minister, German Federal Ministry of Education and Research (BMBF)

Leveraging the power of collaboration

DNDi co-launched the COVID-19 Clinical Research Coalition in early April 2020 to help fast-track desperately needed research for low-resource settings. More than 250 member representatives from 168 institutions in 56 countries have joined so far, working to complement the efforts of the World Health Organization (WHO) and other stakeholders researching new tools for COVID-19 prevention, diagnosis, and treatment in resource-limited settings. With leadership from experts in low- and middle-income countries (LMICs), members are focused on streamlining complex processes and addressing critical concerns such as ethics review, regulation, manufacturing, clinical trials support and logistics, data sharing, and ensuring equitable and affordable access to new tools.

“Efforts to enhance research capacity, exchange know-how, standardize data collection, and share results rapidly are critical to developing and deploying the tools we need to protect health workers and communities in low-and middle-income countries.”

Professor Sir Nicholas J. White, Chair of Wellcome’s South East Asian Research Units (Thailand and Vietnam), and Chair of DNDi’s Scientific Advisory Committee

Conducting research where it’s needed

DNDi and several expert groups from the COVID-19 Clinical Research Coalition have joined forces in preparing to launch the ANTICOV clinical trial in about 15 African countries. The goal is to identify one or two treatments that can be used to treat mild and moderate cases of COVID-19 early and prevent mass hospitalizations that could wreak havoc on fragile health systems. Led by the ANTICOV Consortium, the trial will compare the current standard of care with other existing repurposed treatments. Additional drugs could be added as the study advances, as the trial is designed to be able to add new potential treatments as they become available or to drop any treatments that are not working. Up to 3,000 patients with mild COVID-19 across over 20 sites could be included.

“It is important that as Africans we do more than just apply the existing scientific knowledge about COVID-19. We should be part of the group that creates this knowledge.”

Dr Evans Amukoye, Director of Scientific Programmes, Kenya Medical Research Institute (KEMRI)
Man being tested for COVID-19

Advocating for accountability

DNDi’s expertise in developing and making treatments available in resource-limited settings is relevant to the COVID-19 response in many ways. As the world mobilizes billions of dollars in unprecedented funding to fight the pandemic, we’re using this expertise to advocate for six commitments that will help make sure that resulting medical advances will also reach people in LMICs:

  1. Target funding and intensify scientific collaboration for research to address the needs of resource-limited settings;
  2. Ensure researchers, public health experts, civil society, and political leaders from Africa, Asia, and Latin America are part of decision making and the global search for treatments, diagnostics, and vaccines
  3. 100% open science – publishing results and data in the open, in real time – because it improves efficiency and accelerates scientific progress;
  4. Make health tools public goods, free of intellectual property restrictions, to ensure affordability and large-scale production
  5. Up-front agreements to ensure sufficient production, equitable allocation, and affordable pricing;
  6. Full transparency on public R&D funding to ensure that both governments and funding recipients are accountable for R&D investments and how they are used.

Resources

  • “Global coalition to accelerate COVID-19 clinical research in resource-limited settings” – The Lancet
    In a comment published in The Lancet in April 2020, a group of scientists, physicians, funders, and policy makers from over 70 institutions in over 30 countries pledged their support for the COVID-19 Clinical Research Coalition.
  • “Africa’s COVID-19 research must be tailored to its realities – by its own scientists” – The Guardian
    Director of DNDi Africa, Dr Monique Wasunna, highlights the urgent need for an African-led clinical research agenda for COVID-19 that prioritizes the specific needs of African patients and front-line medical staff.

Photo credit: KEMRI; Xavier Vahed-DNDi

Clinical trials Partnership Pandemic Preparedness

Read, watch, share

Loading...
Centre of Excellence in India
News
14 Sep 2023

DNDi’s Centres of Excellence: Towards the sustainable elimination of visceral leishmaniasis in India

Delali Attip
Press releases
6 Sep 2023

Biotech leader Delali Attiogbe Attipoe joins DNDi as North America Director

Viewpoints
5 Sep 2023

Africa should bolster research into climate-sensitive diseases

Context
Prof. Sam Kariuki, DNDi Eastern Africa Director and Leonard Ithau, Rotary International District 9212 District Governor shaking hands
News
29 Aug 2023

DNDi and Rotary collaborate to prevent and treat diseases affecting neglected communities in Eastern Africa

Mother and child in a hospital
Viewpoints
24 Aug 2023

A drug development model for the diseases the world forgot

Africa Arguments
Statements
21 Aug 2023

DNDi urges G20 to operationalize equity in response to major global health challenges and priorities

Man looking into a microscope
Press releases
31 Jul 2023

Certara and DNDi partnering to fast-track data submissions and accelerate drug approvals for neglected patients

DNDi Prof. Fahal Interview 2023 Cover Image
Videos
25 Jul 2023

Prof. Fahal On The 20 Years of Innovating Together In Helping Mycetoma Patients

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
This website uses necessary cookies to function. If you give your consent, we will also use statistical, functional, and marketing cookies. See Cookie Policy.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo